New pill aims to control hepatitis b and boost immune response

NCT ID NCT07307586

Recruiting now Disease control Sponsor: Zhigang Ren Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tests azvudine tablets in 120 people with chronic hepatitis B. The drug works by both fighting the virus and activating the immune system. Researchers will monitor viral load, liver function, and immune activity over 12 months to see if azvudine can help achieve clinical cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Azvudine tablets
What this could lead to: If successful, this could offer a new treatment option that controls hepatitis B virus and may lead to a clinical cure for some patients.
What could go wrong: This is a small early-phase study with only 120 participants, so results may not apply to everyone. The treatment may cause side effects or fail to control the virus long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AZVUDINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AZVUDINE CHRONIC HEPATITIS B

Contacts and locations

Locations

The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.